• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Nevro Corp.

    4/14/25 8:30:09 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care
    Get the next $NVRO alert in real time by email
    15-12G 1 d924813d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number: 001-36715

     

     

    NEVRO CORP.*

    (Exact name of registrant as specified in its charter)

     

     

    c/o Globus Medical, Inc.

    2560 General Armistead Avenue,

    Audubon, PA 19403

    (610) 930-1800

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, $0.001 par value per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: 1*

     

    *

    On April 3, 2025, Nevro Corp., a Delaware corporation (“Nevro”), completed the previously announced merger of Palmer Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a direct wholly owned subsidiary of Globus Medical, Inc., a Delaware corporation (“Globus”), with and into Nevro (the “Merger”), with Nevro surviving the Merger as a wholly owned subsidiary of Globus. The Merger was effectuated pursuant to the Agreement and Plan of Merger, dated as of February 6, 2025, by and among Globus, Merger Sub and Nevro.

    Pursuant to the requirements of the Securities Exchange Act of 1934, Nevro Corp. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: April 14, 2025     NEVRO CORP.
        By:  

    /s/ Keith Pfeil

        Name:   Keith Pfeil
        Title:   Chief Operating Officer and Chief Financial Officer

     

     

     

    Get the next $NVRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVRO

    DatePrice TargetRatingAnalyst
    2/10/2025$4.50 → $5.85Underperform → Hold
    Jefferies
    2/7/2025$6.00 → $5.85Neutral → Overweight
    Piper Sandler
    12/3/2024$5.00Equal Weight
    Wells Fargo
    12/2/2024$9.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    8/9/2024Sell → Neutral
    Citigroup
    8/8/2024Underperform → Peer Perform
    Wolfe Research
    8/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024Neutral → Underweight
    JP Morgan
    More analyst ratings